|
ApoImmune, Inc. Awarded NCI Phase I SBIR Grant for Vaccine Development
September 1, 2005 (Louisville, KY) - ApoImmune, Inc. announced today that it has been awarded a two-year Phase I Small Business Innovation Research (SBIR) grant of $769,229 from the National Institutes of Health. Funding from the grant will be used to develop a novel immunotherapy based on the Company's ProtEx technology. The two-year Phase I SBIR grant was awarded by the National Cancer Institute (NCI). This is the Company's fourth NIH SBIR/STTR award.
The SBIR was awarded to develop ApoImmune's ProtEx technology into a lead cancer vaccine. Proof-of-principle for ProtEx as an effective immunotherapeutic approach was demonstrated in preclinical and ex vivo human studies.
"Awarding of this grant is a significant step in our efforts to develop a unique therapeutic treatment for cancer patients," said Steven Downey, President and CEO of ApoImmune. "Our ongoing plans for our immunotherapy and vaccine program are to establish its safety and efficacy as a therapeutic vaccine for cervical cancer."
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
About ApoImmune, Inc.
ApoImmune Inc. is a Louisville, Kentucky-based biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. The Company's lead immunotherapy is based on the ProtEx technology's ability to teach the immune system to recognize foreign pathogens as harmful and specifically target those harmful cells for destruction. ApoImmune is also developing ProtEx to suppress the immune system in certain cases, which improves current organ and tissue transplant therapies by protecting the transplant from being attacked by the recipient's immune system when transplanted into the body. An added benefit of the ProtEx immune system suppression technology is that it also reduces the need for powerful immunosuppressive drugs with highly toxic effects that are required after transplantation.
For more information, visit www.apoimmune.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
back to Latest News
|
|
|
